Interpretation of 17-hydroxyprogesterone levels in early neonatal period by dissociation-enhanced lanthanide fluorescent immunoassay technique in a tertiary care centre

Arasar Seeralar, Ganesh Jayachandran, Padmanaban Srinivasan


Background: Mass screening for CAH is controversial worldwide because of the low positive predictive value. The cut off levels of 17 OHP in NBS are based on birth weight and or gestational age. Both RIAs and ELISAs have been almost replaced in most European countries by DELFIA. We used DELFIA technique. The aim and objective was to determine optimal cut off values of 17 OHP levels in early neonatal period based on gestational age and birth weight.

Methods: The study was conducted in the neonatal unit of RSRM Hospital Stanley Medical College as Prospective cross sectional study. All new borns with a gestational age of 34 weeks or more were included in the study. Sample was collected after getting informed consent after 48 hours of age till 7 days of age. 1695 babies who met the inclusion criteria were enrolled, the blood sample were collected by heel prick on filter paper. Neonates less than 34 weeks of gestational age, babies mothers who had received antenatal steroids, babies who had received blood transfusion prior to sampling and refusal of consent were excluded

Results: As the gestational age increases the mean 17 OHP values declines and plateaus at 37 weeks and beyond. Similarly analysis based on weight shows a decline in mean values of 17 OHP with increasing birth weight and plateaus from 2500 gm.

Conclusions: The study demonstrates clearly that there is linear trend in mean 17 OHP values in relationship to gestational age when compared to birth weight.



17 OHP mean values, Neonatal screening, DELFIA

Full Text:



van der Kamp HJ1, Oudshoorn CG, Elvers BH, van Baarle M, Otten BJ, Wit JM et al. Cut off Levels of 17-Hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metabol. 2005;90(7):3904-7.

Gruneiro de Papendieck L, Prieto L. Congenital adrenal hyperplasia and early newborn screening: 17á-hydroxyprogesterone (17á-OHP) during the first days of life. J Med Screen. 1998;5:24-6.

Al Saedi S, Dean H, Dent W, Cronin C. Reference ranges for serum cortisol and 17-hydroxyprogesterone levels in preterm infants. J Pediatr. 1995;126:985-7.

Qazi QH, Thompson WM. Birth weight in congenital virilizing adrenal hyperplasia. Arch Dis Child. 1971;46:350-2.

Pang S, Shook MK. Current status of neonatal screening for congenital adrenal hyperplasia. Curr Opin Pediatr. 1997;9:419-23.

Larsson A, Thile´n A, Hagenfeldt L, Do¨beln von U, Guthenberg C. Screening of half a million Swedish newborn infants for congenital adrenal hyperplasia. Screen. 1992;1:159-66.

Cutfield WS, Webster D. Newborn screening for congenital adrenal hyperplasia in New Zealand. J Pediatr. 1995;126:118-21.